Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders.

Weinland SR, Morris CB, Dalton C, Hu Y, Whitehead WE, Toner BB, Diamant N, Leserman J, Bangdiwala SI, Drossman DA.

Am J Gastroenterol. 2010 Jun;105(6):1397-406. doi: 10.1038/ajg.2009.748. Epub 2010 Jan 19.

PMID:
20087332
2.

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.

Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI.

Gastroenterology. 2003 Jul;125(1):19-31.

PMID:
12851867
3.

Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment.

Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Dalton CB, Leserman J, Patrick DL, Bangdiwala SI.

Am J Gastroenterol. 2007 Jul;102(7):1442-53. Epub 2007 May 17.

PMID:
17509027
4.

Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage.

Halpert A, Dalton CB, Diamant NE, Toner BB, Hu Y, Morris CB, Bangdiwala SI, Whitehead WE, Drossman DA.

Am J Gastroenterol. 2005 Mar;100(3):664-71.

PMID:
15743366
5.

What determines severity among patients with painful functional bowel disorders?

Drossman DA, Whitehead WE, Toner BB, Diamant N, Hu YJ, Bangdiwala SI, Jia H.

Am J Gastroenterol. 2000 Apr;95(4):974-80.

PMID:
10763947
6.

Further characterization of painful constipation (PC): clinical features over one year and comparison with IBS.

Drossman DA, Morris C, Hu Y, Leserman J, Dalton C, Toner B, Diamante N, Bangdiwala S.

J Clin Gastroenterol. 2008 Nov-Dec;42(10):1080-8.

PMID:
18949838
7.

Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial.

McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, Petkova E.

Drug Alcohol Depend. 2005 Nov 1;80(2):209-21.

PMID:
15913920
8.

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, Jia H, Bangdiwala SI.

Am J Gastroenterol. 2000 Apr;95(4):999-1007.

PMID:
10763950
9.

The development of a cognitive scale for functional bowel disorders.

Toner BB, Stuckless N, Ali A, Downie F, Emmott S, Akman D.

Psychosom Med. 1998 Jul-Aug;60(4):492-7.

PMID:
9710296
10.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626
11.

Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study.

Boyce P, Gilchrist J, Talley NJ, Rose D.

Aust N Z J Psychiatry. 2000 Apr;34(2):300-9.

PMID:
10789535
12.

History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.

Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA.

World J Biol Psychiatry. 2009;10(4 Pt 2):435-41. doi: 10.1080/15622970902789155.

PMID:
19382010
13.

Symptom relief with amitriptyline in the irritable bowel syndrome.

Rajagopalan M, Kurian G, John J.

J Gastroenterol Hepatol. 1998 Jul;13(7):738-41.

PMID:
9715427
14.

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, Dow MG, Gumley AI.

Health Technol Assess. 2005 Nov;9(42):1-174. Review.

15.

Health-related quality of life in subjects with functional bowel disorders in Germany.

Icks A, Haastert B, Enck P, Rathmann W, Giani G.

Z Gastroenterol. 2002 Oct;40(10):863-7.

PMID:
12436352
16.

Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.

Han C, Masand PS, Krulewicz S, Peindl K, Mannelli P, Varia IM, Pae CU, Patkar AA.

J Clin Pharm Ther. 2009 Feb;34(1):79-88. doi: 10.1111/j.1365-2710.2008.00975.x.

PMID:
19125906
17.

Cumulative response curves to enhance interpretation of treatment differences on the Self-Esteem And Relationship questionnaire for men with erectile dysfunction.

Cappelleri JC, Zou KH, Bushmakin AG, Carlsson MO, Symonds T.

BJU Int. 2013 Mar;111(3 Pt B):E115-20. doi: 10.1111/j.1464-410X.2012.11489.x. Epub 2012 Sep 27.

18.

Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence.

Sofuoglu M, Gonzalez G, Poling J, Kosten TR.

Am J Drug Alcohol Abuse. 2003;29(4):713-27.

PMID:
14713135
19.

Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, Guthrie E, Read N, Thompson D.

Ann Intern Med. 2001 May 1;134(9 Pt 2):860-8.

PMID:
11346322
20.

Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.

Mathias JR, Clench MH, Abell TL, Koch KL, Lehman G, Robinson M, Rothstein R, Snape WJ.

Dig Dis Sci. 1998 Jun;43(6):1347-55.

PMID:
9635630
Items per page

Supplemental Content

Write to the Help Desk